Article

Tratamientos farmacológicos en primeros episodios psicóticos: Niveles de glutamato y BDNF.

Source: OAI

ABSTRACT Comunicación presentada en: 11º Congreso Virtual de Psiquiatría. Interpsiquis 2010. Psiquiatria.com. Febrero-Marzo de 2010. INTRODUCCIÓN. El BDNF y el glutamato están implicados en la etiología de la esquizofrenia y otros trastornos psicóticos al desempeñar un papel importante en la regulación de la excitación neuronal. OBJETIVOS 1. Determinar los niveles de glutamato y BDNF en un grupo de personas con un primer episodio psicótico (PEP) y compararlos con los de un grupo control. 2. Analizar los cambios en el glutamato y BDNF a lo largo de un año en un el grupo de personas con un PEP y como influye el tratamiento farmacológico. METODOLOGÍA: La muestra estaba compuesta por 108 sujetos. 54 pacientes que cumplían criterios DSM IV para un trastorno psicótico y 54 voluntarios pareados por sexo, edad y nivel socioeconómico que formaban el grupo control. Los niveles de BDNF y glutamato se analizaron en 4 momentos: al momento de aparecer el episodio, al mes, a los 6 meses y a un año. RESULTADOS Los niveles de glutamato y BDNF fueron significativamente inferiores en los sujetos con un PEP en la muestra recogida en el primer episodio y al mes. A los 6 meses y al año de seguimiento no se encontraron diferencias significativas. Durante el seguimiento a los 6 meses los niveles de glutamato y BDNF incrementaron en el grupo experimental. CONCLUSIONES Los niveles en plasma del BDNF y el glutamato disminuyen al inicio de la psicosis; con el tratamiento farmacológico los niveles de glutamato y BDNF aumentan significativamente pero son necesarios 6 meses de tratamiento para conseguir niveles normales.

0 Bookmarks
 · 
95 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We show here that clozapine, a beneficial antipsychotic, down-regulates the expression of the glutamate transporter GLT-1 in the rat cerebral cortex, thereby reducing glutamate transport and raising extracellular glutamate levels. Clozapine treatment (25--35 mg kg(-1) day(-1) orally) reduced GLT-1 immunoreactivity in several brain regions after 3 weeks; this effect was most prominent after 9 weeks and most evident in the frontal cortex. GLT-1 protein levels were reduced in the cerebral cortex of treated rats compared with controls and were more severely affected in the anterior (71.9 +/- 4.5%) than in the posterior (53.2 +/- 15.4%) cortex. L-[(3)H]-glutamate uptake in Xenopus laevis oocytes injected with mRNA extracted from the anterior cerebral cortex of rats treated for 9 weeks was remarkably reduced (to 30.6 +/- 8.6%) as compared to controls. In addition, electrophysiological recordings from oocytes following application of glutamate revealed a strong reduction in glutamate uptake currents (46.3 +/- 10.2%) as compared to controls. Finally, clozapine treatment led to increases in both the mean basal (8.1 +/- 0.7 microM) and the KCl-evoked (28.7 +/- 7.7 microM) output of glutamate that were 3.1 and 3.5, respectively, higher than in control rats. These findings indicate that clozapine may potentiate glutamatergic synaptic transmission by regulating glutamate transport.
    Molecular Psychiatry 08/2001; 6(4):380-6. · 14.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A long duration of untreated psychosis (DUP) is associated with relatively poor clinical and social outcomes. In order to identify whether an anatomically mediated mechanism may give rise to poorer outcomes, it is important to identify whether a long DUP is associated with greater brain structural abnormalities. 81 patients with first-episode psychosis (schizophrenia, affective, and other psychoses) were scanned using high resolution Magnetic Resonance Imaging. DUP was defined as the number of days between first onset of psychotic symptoms and first contact with mental health services. High-resolution MRI images and voxel-based methods of image analysis were used to investigate brain structure in these patients. Longer DUP was associated with gray matter reductions in left middle and inferior temporal, left occipital and left fusiform cortices, and with gray matter excess of the left basal ganglia. All findings remained significant when co-varying for exposure to antipsychotic treatment. Temporal gray matter reductions are more marked in patients with a long DUP. This could reflect a progressive pathological process that is active prior to treatment. Alternatively, these abnormalities could be associated with a more insidious onset of illness and a later presentation to services.
    Schizophrenia Research 05/2006; 83(2-3):145-53. · 4.59 Impact Factor